ArticleFrontiers in cellular and infection microbiology2020
Molecular Epidemiology and Risk Factors of
Article in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- The prevalence and molecular epidemiology ofEmerging microbes & infections · 2026Observational
- Review
- Article
- Biliverdin targeting TcdB-DRBD inhibits Clostridioides difficile virulence and restores gut microbiota in Mongolian gerbils (Meriones unguiculatus).Communications biology · 2025Article
- The Global Burden ofInfectious disease reports · 2025Review
- Multi-drug resistantFrontiers in cellular and infection microbiology · 2025Article
- Recent development and fighting strategies for lincosamide antibiotic resistance.Clinical microbiology reviews · 2024Review
- Molecular characteristics, clonal transmission, and risk factors ofFrontiers in microbiology · 2024Article
- Genomic Epidemiology ofInfection and drug resistance · 2024Article
- Genomic and phenotypic characterization of aFrontiers in cellular and infection microbiology · 2024Article
- An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.BMC infectious diseases · 2023Article
- Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.Antimicrobial agents and chemotherapy · 2023Article
- Host Sorbitol and Bacterial Sorbitol Utilization Promote Clostridioides difficile Infection in Inflammatory Bowel Disease.Gastroenterology · 2023Article
- Assessment of independent comorbidities and comorbidity measures in predicting healthcare facility-onset Clostridioides difficile infection in Kenya.PLOS global public health · 2022Article
- Complete Genome Sequencing and Comparative Phenotypic Analysis Reveal the Discrepancy BetweenFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of Methods: From September 2014 to August 2019, 562 Results: The incidence of inpatients with CDI was 7.06 cases per 10,000 patient-days. Of the 562 C Conclusion: This study revealed the molecular epidemiology and risk factors for the dominant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.